{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T18:57:11Z","timestamp":1781463431376,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijid.2026.108671","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:08:07Z","timestamp":1774883287000},"page":"108671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of albuvirtide intensification for low-level viremia in people with HIV-1: A retrospective pilot study"],"prefix":"10.1016","volume":"168","author":[{"given":"Chuantiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuantao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108671_bib0001","article-title":"Prevalence of low-level viremia and related influencing factors among people living with HIV in China: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2025","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.ijid.2026.108671_bib0002","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12879-023-08906-5","article-title":"Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study","volume":"24","author":"Lao","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2026.108671_bib0003","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy","volume":"204","author":"Taiwo","year":"2011","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.ijid.2026.108671_bib0004","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/sextrans-2024-056199","article-title":"Management of low-level HIV viremia during antiretroviral therapy: Delphi consensus statement and appraisal of the evidence","volume":"100","author":"Rindi","year":"2024","journal-title":"Sex Transm Infect"},{"issue":"2","key":"10.1016\/j.ijid.2026.108671_bib0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/aid.2023.0015","article-title":"Factors associated with low-level viremia in people living with HIV in the Italian antiviral response cohort analysis cohort: a case\u2013control study","volume":"40","author":"Lombardi","year":"2024","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.ijid.2026.108671_bib0006","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/v13020228","article-title":"Injectable antiretroviral drugs: back to the future","volume":"13","author":"Berruti","year":"2021","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.ijid.2026.108671_bib0007","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s40121-021-00540-5","article-title":"Tolerability and adherence of antiretroviral regimens containing long-acting fusion inhibitor albuvirtide for HIV post-exposure prophylaxis: a cohort study in China","volume":"10","author":"Nie","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"3","key":"10.1016\/j.ijid.2026.108671_bib0008","first-page":"1987","article-title":"Investigational drugs in HIV: pros and cons of entry and fusion inhibitors (Review)","volume":"19","author":"Venanzi Rullo","year":"2019","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.ijid.2026.108671_bib0009","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12981-023-00560-w","article-title":"Rescue therapy with an albuvirtide-based antiretroviral regimen in an HIV-infected child with multidrug resistance and multiple opportunistic infections: a case report","volume":"20","author":"Tang","year":"2023","journal-title":"AIDS Res Ther"},{"issue":"1","key":"10.1016\/j.ijid.2026.108671_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/aid.2014.0194","article-title":"Potential implication of residual viremia in patients on effective antiretroviral therapy","volume":"31","author":"Sahu","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"45","key":"10.1016\/j.ijid.2026.108671_bib0011","doi-asserted-by":"crossref","first-page":"35344","DOI":"10.1097\/MD.0000000000035344","article-title":"Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV\/AIDS","volume":"102","author":"Liu","year":"2023","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.ijid.2026.108671_bib0012","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12977-025-00662-5","article-title":"Therapeutic efficacy of albuvirtide-based antiretroviral therapy in people living with HIV who have low-level viremia and non-AIDS-defining malignancies: two case reports","volume":"22","author":"Zhang","year":"2025","journal-title":"Retrovirology"},{"key":"10.1016\/j.ijid.2026.108671_bib0013","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV [Internet]. Washington (DC): U.S. Department of Health and Human Services; 2023 [cited 2026 Apr 21]."},{"issue":"7","key":"10.1016\/j.ijid.2026.108671_bib0014","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society\u2013USA panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ijid.2026.108671_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciac762","article-title":"Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort","volume":"76","author":"Elvstam","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2026.108671_bib0016","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1\u2013infected patients experiencing persistent low-level viremia during first-line therapy","volume":"204","author":"Taiwo","year":"2011","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2026.108671_bib0017","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","article-title":"The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation","volume":"29","author":"Wada","year":"2015","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.ijid.2026.108671_bib0018","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/phar.2914","article-title":"Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and\/or have multidrug-resistant HIV-1: endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy","volume":"44","author":"Cluck","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijid.2026.108671_bib0019","doi-asserted-by":"crossref","unstructured":"Waters, L., Winston, A., Walsh, J.C. (2022). BHIVA guidelines on antiretroviral treatment for adults living with HIV\u20101 2022. HIV Medicine, 23(S5), 3\u2013115. doi:10.1111\/hiv.13446.","DOI":"10.1111\/hiv.13446"},{"issue":"7","key":"10.1016\/j.ijid.2026.108671_bib0020","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/sextrans-2024-056199","article-title":"Management of low-level HIV viremia during antiretroviral therapy: Delphi consensus statement and appraisal of the evidence","volume":"100","author":"Rindi","year":"2024","journal-title":"Sex Transm Infect"},{"issue":"1","key":"10.1016\/j.ijid.2026.108671_bib0021","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/ciae569","article-title":"HIV-1 low-level viremia predicts viral failure in participants on antiretroviral therapy in the Swiss HIV Cohort Study","volume":"81","author":"Lanz","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108671_bib0022","doi-asserted-by":"crossref","unstructured":"Liang G., Huang Y., Wang J., Gao X., Zhao Y., Ga L., et al. Peptide\u2011based fusion inhibitors targeting 6\u2011HB: resistance to HIV\u20111 outside of cells. In: Saxena S\u2011K, editor. Viral Infectious Diseases Annual Volume2025 . London, UK: IntechOpen; 2025 Jul 18 [cited 2026 Apr 21].","DOI":"10.5772\/intechopen.1011082"},{"key":"10.1016\/j.ijid.2026.108671_bib0023","article-title":"Second-line ART after treatment failure or for regimen simplification","volume":"2","author":"Merrick","year":"2025","journal-title":"Med Care"},{"issue":"11","key":"10.1016\/j.ijid.2026.108671_bib0024","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1002\/jmv.28005","article-title":"Cell-to-cell transmission of HIV-1 from provirus-activated cells to resting na\u00efve and memory human primary CD4 T cells is highly efficient and requires CD4 and F-actin but not chemokine receptors","volume":"94","author":"Lan","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijid.2026.108671_bib0025","first-page":"10","article-title":"Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed HIV-1 adults: a 24-week study","volume":"1097","author":"Fu","year":"2022","journal-title":"AIDS"},{"issue":"24","key":"10.1016\/j.ijid.2026.108671_bib0026","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1097\/CM9.0000000000001273","article-title":"Talent Study Team. Efficacy and safety of the long\u2011acting fusion inhibitor albuvirtide in antiretroviral\u2011experienced adults with human immunodeficiency virus\u20111: interim analysis of the randomized, controlled, phase 3, non\u2011inferiority TALENT study","volume":"133","author":"Su","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ijid.2026.108671_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1397743","article-title":"Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders","volume":"14","author":"Fan","year":"2024","journal-title":"Front Cell Infect Microbiol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226003061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226003061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T18:19:33Z","timestamp":1781461173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226003061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"alternative-id":["S1201971226003061"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108671","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of albuvirtide intensification for low-level viremia in people with HIV-1: A retrospective pilot study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108671"}}